PHVS Pharvaris N.V.

QT74

NASDAQ·Healthcare·Biotechnology·Switzerland

Latest market price

33.53

+0.00%

Overview Short InterestFilings

PHVSQT74Pharvaris N.V.·NASDAQ

Overview Short InterestFilings

33.53+0.00%

Loading chart...

Signal & projected range

QT Score downgradeHistorical pattern — not a prediction

Range still being built for this setupWe don’t yet have a frozen historical track record for qt score downgrade to describe a reliable spread of outcomes. The projected range appears once its backtest is established.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

IMNM+7.58%$19.59 BHVN-1.69%$15.16 NAMS-2.49%$19.56 RXRX-4.96%$3.83 CLDX-3.52%$29.04 RCUS-1.87%$17.85 ZLAB-1.81%$21.67 ADMA-3.07%$11.06

Snapshot

Index	—	P/E	—	EPS (ttm)	-3.15	Insider Own	2.63%	Shs Outstand	69.86M	Perf Week	6.31%

Market Cap	2.34B	Forward P/E	—	EPS next Y	-3.03	Insider Trans	-42.79%	Shs Float	33.60M	Perf Month	7.50%

Enterprise Value	1.98B	PEG	—	EPS next Q	-0.92			Short Float	7.34%	Perf Quarter	-1.00%

Income	-200.00M	P/S	—	EPS this Y	—			Short Ratio	3.33	Perf Half Y	11.69%

Sales	0.00	P/B	6.83	EPS next Y	—	ROA	-52.20%	Short Interest	2.47M	Perf YTD	20.83%

Book/sh	4.91	P/C	6.45	EPS next 5Y	—	ROE	-61.24%	52W High	43.25 -22.47%	Perf Year	50.76%

Cash/sh	5.20	P/FCF	—	EPS past 3/5Y	—	ROIC	-60.72%	52W Low	21.02 59.51%	Perf 3Y	83.22%

Dividend Est.	—	EV/EBITDA	—	Sales past 3/5Y	—	Gross Margin	0.00%	Volatility	3.05% 4.14%	Perf 5Y	106.98%

Dividend TTM	—	EV/Sales	—	EPS Y/Y TTM	—	Oper. Margin	0.00%	ATR (14)	1.33	Perf 10Y	—

Dividend Ex-Date	—	Quick Ratio	11.94	Sales Y/Y TTM	—	Profit Margin	0.00%	RSI (14)	59.57	Recom	2.00

Dividend Gr. 3/5Y	—	Current Ratio	11.94	EPS Q/Q	13.83%	SMA20	7.52%	Beta	-2.63	Target Price	62.00

Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	—	SMA50	-0.24%	Rel Volume	0.77	Prev Close	33.53

Employees	148	LT Debt/Eq	0.00	Earnings	Nov 11	SMA200	8.04%	Avg Volume	816.90K	Price	33.53

IPO Date	Feb 04, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-6.75% —	Net Debt/EBITDA	—	Volume	633,045	Change	0.00%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Oct-23-26	Upgrade	B of A Securities	Neutral → Buy
Oct-06-26	Reiterated	UBS		$79 → $60
Sep-14-26	Reiterated	Cantor Fitzgerald	Overweight	$65
Sep-10-26	Reiterated	Guggenheim	Buy	$40 → $44
Sep-09-26	Reiterated	Rosenblatt Securities		$60
Sep-09-26	Reiterated	UBS		$75 → $79
Sep-09-26	Reiterated	Leerink Partners	Outperform	$38 → $65
Sep-09-26	Reiterated	Morgan Stanley	Overweight	$46 → $62
Sep-09-26	Reiterated	Wedbush	Outperform	$27 → $50
Sep-09-26	Reiterated	RBC Capital	Outperform	$52 → $62

Latest News· Times ET

Oct-29-26

Oct-29-2606:50AM

Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meetingglobenewswire.com

Oct-26-26

Oct-26-2607:00PM

Bank of America backs Pharvaris on breakthrough for rare swelling diseaseYahoo

Oct-23-26

Oct-23-2602:06PM

Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fadebenzinga.com

Oct-21-26

Oct-21-2604:05AM

12 Health Care Stocks Moving In Wednesday's Pre-Market SessionBenzinga

Oct-15-26

Oct-15-2602:05PM

BioCryst (BCRX) Trades at Just 11x Forward Earnings. Is the Market Pricing In Trouble?Yahoo

Oct-08-26

Oct-08-2611:05PM

Reported Earlier, Pharvaris Says Lancet-Published Phase 3 Data Show Deucrictibant IR Delivered Symptom Relief In 1.28 Hours And Complete Resolution In 11.95 Hours For HAE Attacks, With NDA And MAA Under ReviewBenzinga

06:35PM

Phase 3 Study Results Highlighting Deucrictibant's Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancetglobenewswire.com

Oct-05-26

Oct-05-2606:50AM

Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in TherapyYahoo

Sep-22-26

Sep-22-2604:53AM

Pharvaris (NASDAQ:PHVS) Director Robert Glassman Sells 14,493 Shares of Stockdefenseworld.net

04:53AM

Pharvaris (NASDAQ:PHVS) Insider Anne Lesage Sells 20,000 Sharesdefenseworld.net

Sep-19-26

Sep-19-2611:12AM

What Does Pharvaris (PHVS) Phase 3 HAE Success Mean Now?Yahoo

Sep-16-26

Sep-16-2605:10AM

Anne Lesage Sells 30,000 Shares of Pharvaris (NASDAQ:PHVS) Stockdefenseworld.net

04:37AM

Pharvaris N.V. $PHVS Position Trimmed by Squarepoint Ops LLCdefenseworld.net

Sep-15-26

Sep-15-2605:41PM

Pharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcriptseekingalpha.com

10:51AM

PHVS Stock Rises 10% in a Month: What Is Driving the Rally?zacks.com

Company

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	0	0	0	0	—	—	—	—	—
Cost of Goods Sold Incl. D&A	0	0	0	0	—	—	—	—	—
Gross Profit	0	0	0	0	—	—	—	—	—
Selling, General and Administrative Excl. Other	63	51	51	34	—	—	—	—	—
Research and Development	152	140	107	71	—	—	—	—	—
Other Operating Expense	-2	1	0	0	—	—	—	—	—
Operating Income	-213	-192	-158	-105	—	—	—	—	—
Interest Expense	0	0	0	0	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	16	-4	14	-3	—	—	—	—	—
Net Income Before Taxes	-197	-196	-143	-108	—	—	—	—	—
Income Taxes	3	2	2	1	—	—	—	—	—
Consolidated Net Income	-200	-198	-145	-109	—	—	—	—	—
Net Income From Continuing Operations	-200	-198	-145	-109	—	—	—	—	—
Net Income	-200	-198	-145	-109	—	—	—	—	—
EPS (Recurring)	-3.15	-3.35	-2.68	-2.84	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-3.15	-3.35	-2.68	-2.84	—	—	—	—	—
EPS (Diluted)	-3.15	-3.35	-2.68	-2.84	—	—	—	—	—
EBITDA	-201	-195	-157	-108	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—	—	—
Shares Outstanding	68	59	54	38	—	—	—	—	—
Market Capitalization	2,280	1,637	1,035	1,066	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Monges Viviane	Director	Sep 23 '26	Option Exercise	8.05	11,969	96,350	17,469	Sep 25
Monges Viviane	Director	Sep 23 '26	Sale	33.05	11,969	395,524	5,500	Sep 25
Lu Peng	President	Sep 22 '26	Option Exercise	2.59	45,308	117,348	110,261	Sep 24
Schikan Johannes Gerardus Christiaan Petrus	Director	Sep 22 '26	Option Exercise	20.00	800	16,000	115,967	Sep 24
Schikan Johannes Gerardus Christiaan Petrus	Director	Sep 22 '26	Sale	36.19	800	28,952	115,167	Sep 24
Nassif David W.	CFO / CLO	Sep 21 '26	Sale	36.47	6,000	218,801	114,300	Sep 23
Schikan Johannes Gerardus Christiaan Petrus	Director	Sep 17 '26	Sale	35.00	200,000	7,000,000	115,167	Sep 21
Bjork Elisabeth	Director	Sep 17 '26	Option Exercise	15.64	52,500	821,100	67,667	Sep 21
Bjork Elisabeth	Director	Sep 17 '26	Sale	37.89	52,500	1,989,409	15,167	Sep 21
Glassman Robert	Director	Sep 17 '26	Sale	38.56	14,493	558,812	10,500	Sep 21
Lesage Anne	Chief Early Development	Sep 17 '26	Sale	38.27	20,000	765,466	73,969	Sep 21
Modig Berndt	Chief Executive Officer	Sep 17 '26	Option Exercise	35.00	300,000	10,500,000	650,000	Sep 21
Glassman Robert	Director	Sep 17 '26	Option Exercise	18.14	14,493	262,903	24,993	Sep 21
Lu Peng	President	Sep 17 '26	Option Exercise	2.59	200,000	518,000	164,953	Sep 21
Lu Peng	President	Sep 17 '26	Sale	35.00	100,000	3,500,000	64,953	Sep 21

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.